Vanguard Group Inc. Grows Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Vanguard Group Inc. increased its position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 2.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,681,111 shares of the company's stock after purchasing an additional 177,961 shares during the period. Vanguard Group Inc. owned approximately 2.14% of GoodRx worth $48,875,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC boosted its stake in GoodRx by 12.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 17,148 shares of the company's stock worth $80,000 after purchasing an additional 1,945 shares in the last quarter. Dimensional Fund Advisors LP raised its position in GoodRx by 12.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 19,383 shares of the company's stock worth $91,000 after buying an additional 2,153 shares during the last quarter. Raymond James & Associates raised its position in GoodRx by 24.0% in the 1st quarter. Raymond James & Associates now owns 13,806 shares of the company's stock worth $267,000 after buying an additional 2,675 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in GoodRx by 22.7% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 14,995 shares of the company's stock worth $84,000 after buying an additional 2,771 shares during the last quarter. Finally, Stifel Financial Corp raised its position in GoodRx by 0.8% in the 3rd quarter. Stifel Financial Corp now owns 346,797 shares of the company's stock worth $1,952,000 after buying an additional 2,920 shares during the last quarter. Institutional investors own 63.77% of the company's stock.

GoodRx Trading Down 1.5 %

GDRX traded down $0.10 during trading on Tuesday, reaching $6.74. The company had a trading volume of 859,380 shares, compared to its average volume of 1,619,635. The stock has a market cap of $2.66 billion, a P/E ratio of -336.83, a PEG ratio of 3.78 and a beta of 1.42. The business has a 50 day simple moving average of $6.80 and a 200-day simple moving average of $6.14. GoodRx Holdings, Inc. has a 52 week low of $4.14 and a 52 week high of $9.37. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.85.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.02. The company had revenue of $196.64 million during the quarter, compared to the consensus estimate of $195.59 million. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. On average, equities analysts anticipate that GoodRx Holdings, Inc. will post 0.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GDRX shares. Bank of America lowered shares of GoodRx from a "buy" rating to an "underperform" rating and reduced their price target for the company from $8.00 to $4.50 in a research report on Tuesday, January 2nd. TD Cowen upped their price target on shares of GoodRx from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, March 1st. Truist Financial upped their price target on shares of GoodRx from $7.50 to $8.00 and gave the company a "hold" rating in a research report on Friday, March 1st. UBS Group increased their target price on shares of GoodRx from $5.00 to $8.00 and gave the stock a "neutral" rating in a report on Friday, March 1st. Finally, SVB Leerink began coverage on shares of GoodRx in a report on Monday, February 26th. They issued an "outperform" rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $8.76.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.